Dyadic International (NASDAQ:DYAI) vs. Coya Therapeutics (NASDAQ:COYA) Critical Review

Coya Therapeutics (NASDAQ:COYA) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares Coya Therapeutics and Dyadic International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Volatility & Risk

Coya Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Coya Therapeutics and Dyadic International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1	0	6	0	2.71
Dyadic International	1	0	2	0	2.33

Coya Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 220.11%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 287.05%. Given Dyadic International’s higher possible upside, analysts clearly believe Dyadic International is more favorable than Coya Therapeutics.

Earnings & Valuation

This table compares Coya Therapeutics and Dyadic International”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$8.02 million	14.01	-$21.23 million	($1.07)	-4.48
Dyadic International	$1.33 million	21.18	-$7.36 million	($0.23)	-3.37

Dyadic International has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Summary

Dyadic International beats Coya Therapeutics on 8 of the 14 factors compared between the two stocks.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.